WMSA
LAB icon

Weiss Multi-Strategy Advisers’s Standard BioTools LAB Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-20,400
Closed -$165K – 422
2015
Q3 		$165K Buy
+20,400
New +$321K 0.01% 371

Other funds holding LAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Atom Investors Austin, Texas $1.4B AUM 23.77% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return

Weiss Multi-Strategy Advisers's LAB Position: Q4 2020 in Review

Weiss Multi-Strategy Advisers sold out of Standard BioTools (LAB) in Q4 2020, closing a stake of 10,000 shares — an estimated $74K sold.

Weiss Multi-Strategy Advisers first reported a position in LAB in Q2 2015 and held it in 22 quarters. The position peaked at $1.59M in Q1 2019. 145 funds tracked by Wall St. Rank hold LAB as of Q4 2020.

  • Weiss Multi-Strategy Advisers reported no remaining Standard BioTools position as of Q4 2020 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 10,000 Standard BioTools shares in Q4 2020, an estimated $74K.
  • Weiss Multi-Strategy Advisers first reported a position in Standard BioTools in Q2 2015 and held it in 22 quarters.
  • Weiss Multi-Strategy Advisers's Standard BioTools position peaked at $1.59M in Q1 2019.
  • 145 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2020.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q4 2020, filed 16 Feb 2021.